These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 7878155)
21. 1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans. Eiermann B; Edlund PO; Tjernberg A; Dalén P; Dahl ML; Bertilsson L Drug Metab Dispos; 1998 Nov; 26(11):1096-101. PubMed ID: 9806952 [TBL] [Abstract][Full Text] [Related]
22. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Sachse C; Brockmöller J; Hildebrand M; Müller K; Roots I Pharmacogenetics; 1998 Apr; 8(2):181-5. PubMed ID: 10022755 [No Abstract] [Full Text] [Related]
24. Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling. Lightfoot T; Ellis SW; Mahling J; Ackland MJ; Blaney FE; Bijloo GJ; De Groot MJ; Vermeulen NP; Blackburn GM; Lennard MS; Tucker GT Xenobiotica; 2000 Mar; 30(3):219-33. PubMed ID: 10752638 [TBL] [Abstract][Full Text] [Related]
25. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease. Bordet R; Broly F; Destée A; Libersa C Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190 [No Abstract] [Full Text] [Related]
26. Lack of defect in oxidative hydroxylation of debrisoquine in a patient with halothane hepatitis. Toutoungi M; Magnenat D Eur J Clin Pharmacol; 1990; 38(6):633-4. PubMed ID: 2373140 [No Abstract] [Full Text] [Related]
27. [CYP 2D6 activity profile among patients with depression]. Bidziński A; Koszewska I; Turzyńska D; Kalinowski A; Swiecicki L; Dabrowski M; Torbiński J; Burna-Drazkowic E; Fornal S; Gradzka D; Namysłowska M; Puzyński S; Płaźnik A Psychiatr Pol; 2004; 38(6):1085-92. PubMed ID: 15779672 [TBL] [Abstract][Full Text] [Related]
28. Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains. Küpfer A; Al-Dabbagh SG; Ritchie JC; Idle JR; Smith RL Biochem Pharmacol; 1982 Oct; 31(20):3193-9. PubMed ID: 7150348 [TBL] [Abstract][Full Text] [Related]
29. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826 [TBL] [Abstract][Full Text] [Related]
30. Debrisoquine oxidation in Parkinson's disease. Kallio J; Marttila RJ; Rinne UK; Sonninen V; Syvälahti E Acta Neurol Scand; 1991 Mar; 83(3):194-7. PubMed ID: 2031454 [TBL] [Abstract][Full Text] [Related]
31. [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population]. Dick B; Küpfer A; Molnàr J; Braunschweig S; Preisig R Schweiz Med Wochenschr; 1982 Jul; 112(30):1061-7. PubMed ID: 7123181 [TBL] [Abstract][Full Text] [Related]
33. Verapamil but not nifedipine influences the metabolic ratio of debrisoquine hydroxylation. Sigusch H; Hoffmann A Pharmazie; 1991 Dec; 46(12):888-9. PubMed ID: 1818331 [No Abstract] [Full Text] [Related]
34. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Christensen M; Andersson K; Dalén P; Mirghani RA; Muirhead GJ; Nordmark A; Tybring G; Wahlberg A; Yaşar U; Bertilsson L Clin Pharmacol Ther; 2003 Jun; 73(6):517-28. PubMed ID: 12811361 [TBL] [Abstract][Full Text] [Related]
35. [Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation]. Dayer P; Courvoisier F; Kupfer A; Balant-Gorgia A; Balant L; Fabre J Schweiz Med Wochenschr; 1983 Feb; 113(8):295-7. PubMed ID: 6133350 [TBL] [Abstract][Full Text] [Related]
36. Effect of levomepromazine and metabolites on debrisoquine hydroxylation in the rat. Hals PA; Dahl SG Pharmacol Toxicol; 1994 Nov; 75(5):255-60. PubMed ID: 7870695 [TBL] [Abstract][Full Text] [Related]
37. N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome. Siegmund W; Fengler JD; Franke G; Zschiesche M; Eike O; Eike E; Meisel P; Wulkow R Br J Clin Pharmacol; 1991 Oct; 32(4):467-72. PubMed ID: 1958441 [TBL] [Abstract][Full Text] [Related]
38. Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine. Müller C; Siegmund W; Huupponen R; Kaila T; Franke G; Iisalo E; Zschiesche M Eur J Drug Metab Pharmacokinet; 1993; 18(3):265-72. PubMed ID: 8149945 [TBL] [Abstract][Full Text] [Related]
39. Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population. Vincent-Viry M; Muller J; Fournier B; Galteau MM; Siest G Clin Chem; 1991 Mar; 37(3):327-32. PubMed ID: 2004438 [TBL] [Abstract][Full Text] [Related]
40. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Johansson I; Yue QY; Dahl ML; Heim M; Säwe J; Bertilsson L; Meyer UA; Sjöqvist F; Ingelman-Sundberg M Eur J Clin Pharmacol; 1991; 40(6):553-6. PubMed ID: 1679392 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]